Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
| Website: | www.galmedpharma.com |
| Email: | info@galmedpharma.com |
| Main Phone: | +972 36938448 |
| Address: | 16 Tiomkin Street |
| City / Town: | Tel Aviv |
| Country: | IL |
| Postal Code: | 6578317 |
| Exchange: | NSC |
| CEO: | Allen Baharaff |
| Employees: | 21 |
| NAICS: | Pharmaceutical P |
Everybody knows that biotech ideas can become huge gainers for investors, but understanding the technology platforms, the unmet needs and the valuations can be daunting, especially in spaces where
Galmed Pharmaceuticals (GLMD) is a clinical-stage biopharmaceutical company headquartered in Tel Aviv, Israel,. Four other companies are scheduled for the week of March 10, 2014. The full
The full IPO calendar is available at IPOpremium. Scheduled IPOs are ranked by IPO size. (1) Based in Greenwich, CT, Diamond S Shipping Group (DSG) scheduled a $210 million IPO on the NYSE
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
| Website: | www.galmedpharma.com |
| Email: | info@galmedpharma.com |
| Main Phone: | +972 36938448 |
| Address: | 16 Tiomkin Street |
| City / Town: | Tel Aviv |
| Country: | IL |
| Postal Code: | 6578317 |
| Exchange: | NSC |
| CEO: | Allen Baharaff |
| Employees: | 21 |
| NAICS: | Pharmaceutical P |
Everybody knows that biotech ideas can become huge gainers for investors, but understanding the technology platforms, the unmet needs and the valuations can be daunting, especially in spaces where
Galmed Pharmaceuticals (GLMD) is a clinical-stage biopharmaceutical company headquartered in Tel Aviv, Israel,. Four other companies are scheduled for the week of March 10, 2014. The full
The full IPO calendar is available at IPOpremium. Scheduled IPOs are ranked by IPO size. (1) Based in Greenwich, CT, Diamond S Shipping Group (DSG) scheduled a $210 million IPO on the NYSE
| Last Price 3.93 | Change $ 0. | Change % 0.00 | Tick N/A |
| Bid 3.66 | Bid Size 100.00 | Ask 4.24 | Ask Size 1,400.00 |
| Open 3.91 | High 4.00 | Low 3.81 | Prev Close 3.93 |
| Last Trade | Volume 24,593 | 52 Wk Hi 7.39 | 52 Wk Low 3.02 |
| Market Cap 83 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 21,113,066.00 | EPS (TTM) -0.76 | PE Ratio N/A | Exchange NCM |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 32 | 32 | 32 | 43 |
| Low Target Price Estimate | 14 | 14 | 14 | 30 |
| Mean Target Price Estimate | 20.8 | 20.8 | 20.8 | 33.2 |
| Standard Deviation | 7.4 | 7.4 | 7.4 | 5.54 |
| Date of Most Recent Estimate | 05/23/18 | 05/23/18 | 05/23/18 | 06/14/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| FWP | Free Writing Prospectus | 27 | 2018-06-18 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 33 | 2018-06-18 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 72 | 2018-06-18 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 8 | 2018-06-12 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 20 | 2018-05-09 |
| SC 13G | Statement of beneficial ownership of common stock by certain persons | 14 | 2018-04-16 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 48 | 2018-04-04 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 54 | 2018-04-04 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 5 | 2018-04-03 |
| UPLOAD | Correspondence from the SEC to the Filer | 1 | 2018-04-02 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1.4 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait